FDA approved edge Neomend offers Progel Pleural Air Leak Sealant, the only FDA-approved pleural air leak sealant in the U.S., presenting a clear regulatory and competitive advantage for thoracic surgery product adoption.

Clinical efficacy proof Multi-center U.S. study shows Progel PALS reduces intraoperative air leaks and shortens hospital stays by nearly two days, enabling value-based selling to hospitals focused on outcomes and cost containment.

Hydrogel platform Proprietary hydrogel technology enables expansion into wound sealing, reduction of post-surgical adhesions, and site-specific drug delivery, offering cross-selling opportunities across surgical specialties.

Growth potential Revenue in the low-to-mid seven figures with significant funding indicates readiness for scale; potential partnerships with larger medical device firms to accelerate market penetration and distribution.

Market positioning Target hospitals and surgical centers performing high volumes of lung resections; leverage clinical outcomes, regulatory approval, and cost savings to differentiate from competitors and drive adoption.